Overview

A Study to Assess the Safety and Efficacy of IPN10200 of in Adult Participants With Upper Limb Spasticity.

Status:
Recruiting
Trial end date:
2024-03-29
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ipsen
Treatments:
abobotulinumtoxinA